Attaining threshold antibody cytotoxicity for selective tumor cell destruction: an opinion article

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Cancer cells express various antigens, some at low levels or down-regulated, complicating targeted immunotherapies.
• Existing immunotherapies may struggle to reach sufficient immune complex density on cancer cells for effective cytolysis.
• Cancer/testis antigens are promising targets but often have low baseline expression on malignant cells.

Purpose of the Study:

• To propose a novel immunotherapeutic paradigm for selective cancer cell destruction.
• To achieve a critical threshold density of immune complexes on cancer cells to trigger cytolytic pathways.
• To develop a method that spares normal cells from immune-mediated damage.

Main Methods:

• Application of multiple antibodies targeting various membrane-associated antigens on cancer cells.
• Combined use of antibodies specific for cancer-associated antigens and antigens present on both normal and tumor cells.
• Utilizing suboptimal antibody dosages for antigens expressed on normal cells to prevent their destruction.

Main Results:

• The proposed strategy can achieve a threshold density of immune complexes on malignant cells.
• Co-expression of antigens on cancer cells allows for cumulative effects leading to selective tumor cell destruction.
• The approach enables highly selective elimination of cancer cells without harming normal tissues.

Conclusions:

• This novel immunotherapeutic paradigm offers a highly selective 'immunological knife' for cancer treatment.
• The strategy effectively targets cancer cells by leveraging co-expressed antigens and controlled antibody dosages.
• This approach holds potential for minimizing off-target effects and improving cancer immunotherapy outcomes.